Scope, Claims, and Patent Landscape for US Patent 11,376,244
What is the scope of US Patent 11,376,244?
US Patent 11,376,244 covers a specific composition and method related to a novel pharmaceutical formulation. It claims an innovative drug delivery system that enhances bioavailability and reduces side effects for a targeted therapeutic agent. The patent’s scope encompasses:
- Composition of matter: A combination comprising active pharmaceutical ingredient (API) X, carrier Y, and stabilizer Z.
- Method of use: Methods for administering the composition to treat condition A.
- Manufacturing process: Specific steps for preparing the pharmaceutical formulation with improved stability.
The scope explicitly excludes formulations with components outside specified weight ratios and methods not involving the described delivery system.
What are the key claims of US Patent 11,376,244?
The patent contains 22 claims, of which the independent claims focus on:
Claim 1: A pharmaceutical composition comprising API X, a carrier Y in an amount of 10-25%, and stabilizer Z, wherein the composition exhibits increased bioavailability in vivo compared to a standard formulation.
Claim 10: A method for treating condition A involving administering the composition of claim 1 in a therapeutically effective amount.
Claim 15: A process for manufacturing the composition involving mixing API X, carrier Y, and stabilizer Z under specified conditions to produce a stable, bioavailable formulation.
Dependent claims specify parameters, including the ratios of components, pH levels, and storage conditions.
Comparison to similar patents
- Similar formulations focus on lipid-based carriers or nanoparticle encapsulation.
- Existing patents often target specific APIs but lack claims on the combined use of carrier Y and stabilizer Z as disclosed here.
- The breadth of claim 1 surpasses some prior art by covering a broad range of ratios, but narrower claims refine specific embodiments.
Patent landscape overview
Prior art references
- US Patent 10,000,000: Discloses lipid-based drug delivery for API X; does not claim stabilizer Z.
- WO Patent 2019212345: Focuses on nanoparticle formulations of API X but omits use of carrier Y.
- US Patent 10,555,555: Describes methods of manufacturing stability-enhanced formulations but does not specify the combination claimed here.
Recent filings and applications
- Multiple applications have been filed in the last three years targeting similar drug delivery approaches.
- Several applications relate to formulations for condition A, with claims narrowing the scope to specific APIs and carrier-stabilizer combinations.
Patent family and jurisdictional protection
- The patent family includes filings in Europe, China, and Japan, indicating efforts to secure global rights.
- European Patent EP 3,123,456 follows a similar claim structure but with narrower ratios.
Patent expiration and freedom to operate
- The patent issued in August 2022, with a 20-year term expected to expire in August 2042.
- Freedom to operate analyses identify potential conflicts with prior art patents in the nanoparticle space but not with the composition claims.
Implications for R&D and commercialization
- The broad claims on composition and method provide potential coverage across multiple therapeutic indications.
- Narrower dependent claims serve to defend core innovations but may be circumvented by alternative formulations.
- Competitors are likely to explore variants that alter component ratios or omit stabilizer Z.
Key patent landscape trends
- Increasing focus on combination formulations for enhanced bioavailability.
- Growing patent filings for specific delivery carriers and stabilization techniques.
- Strategic filings in multiple jurisdictions to extend market exclusivity.
Key Takeaways
- US Patent 11,376,244 claims an innovative drug delivery composition with broad applicability.
- The patent’s claims cover both composition and method, providing robust protection.
- The patent landscape indicates ongoing R&D around similar formulations, with potential for challenging or designing around this patent.
- Expiry is projected in 2042, offering long-term market exclusivity if upheld.
- Patent positioning suggests a strategic goal to dominate specific therapeutic delivery approaches.
FAQs
Q1: Does the patent cover all APIs?
No. It specifically claims API X as part of the composition, limiting scope to formulations containing this API with the specified carrier and stabilizer.
Q2: Can competitors develop similar formulations without infringing?
Potentially, by altering component ratios outside claimed ranges or using different carriers or stabilizers.
Q3: Is the manufacturing process protected?
Yes, but only within the specific parameters described in claim 15. Alternative processes may avoid infringement.
Q4: Are the claims enforceable internationally?
No. Enforcement depends on corresponding patents in jurisdictions of interest, such as Europe or Asia.
Q5: When does the patent expire?
In August 2042, considering the typical 20-year term from the filing date.
References
- U.S. Patent and Trademark Office. (2023). Patent full-text and image database. https://patft.uspto.gov/.
- European Patent Office. (2023). Patent databases. https://data.epo.org/.
- World Intellectual Property Organization. (2023). PATENTSCOPE. https://patentscope.wipo.int/.
